# Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer

> **NCT01583777** · PHASE1 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 6 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT01583777
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583777, "Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01583777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*